{"id":"tasocitinib","rwe":[],"tags":[],"phase":"discontinued","safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"status":"discontinued","trials":["NCT04259138","NCT01185184","NCT07138898","NCT05638932","NCT00263328","NCT06172361","NCT06275464","NCT07406932","NCT01786668","NCT01184092","NCT03580343","NCT06095128","NCT01736696","NCT04799262","NCT06301373","NCT00414661","NCT03281304","NCT06278402","NCT03736161","NCT01932372","NCT04018001","NCT03868072","NCT04876781","NCT01309737","NCT06438679","NCT02812342","NCT03643211","NCT05293119","NCT07406035","NCT05048238","NCT03016884","NCT03011281","NCT04412252","NCT04338204","NCT06089590","NCT00658359","NCT01710046","NCT06469424","NCT03703817","NCT03858725","NCT03159936","NCT01204112","NCT06201715","NCT01143805","NCT03793439","NCT01710020","NCT05580042","NCT05431283","NCT05606107","NCT03975790"],"aliases":[],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"aiSummary":"","brandName":"Tasocitinib","companyId":"pfizer","ecosystem":[],"mechanism":{"target":"Aurora kinase B, BMP-2-inducible protein kinase, Calcium/calmodulin-dependent protein kinase type 1","novelty":"","modality":"Small molecule","drugClass":"","explanation":"","oneSentence":"","technicalDetail":""},"commercial":null,"references":[],"biosimilars":[],"companyName":"Pfizer","competitors":[],"dataSources":[{"url":"https://clinicaltrials.gov","name":"ClinicalTrials.gov","fields":["trialDetails","trials"],"retrievedDate":"2026-04-07"},{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"Tasocitinib","indications":{"approved":[{"name":"Juvenile idiopathic arthritis, extended oligoarthritis","diseaseId":"juvenile-idiopathic-arthritis-extended-oligoarthritis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Juvenile psoriatic arthritis","diseaseId":"juvenile-psoriatic-arthritis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Polyarticular juvenile idiopathic arthritis","diseaseId":"polyarticular-juvenile-idiopathic-arthritis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Psoriatic arthritis","diseaseId":"psoriatic-arthritis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Rheumatoid arthritis","diseaseId":"rheumatoid-arthritis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Ulcerative colitis","diseaseId":"ulcerative-colitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT04259138","phase":"Phase 4","title":"VERDICT: In actiVE Ulcerative Colitis, a RanDomIzed Controlled Trial for Determination of the Optimal Treatment Target","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alimentiv Inc.","isPivotal":false,"enrollment":672,"indication":"Colitis, Ulcerative","completionDate":"2026-03-31"},{"nctId":"NCT01185184","phase":"Phase 1","title":"A Phase 1, Randomized, 3-Period, Open Label, Single Dose, Cross Over Study To Evaluate The Pharmacokinetics And Safety Of Two Controlled Release Formulations Of CP-690,550","status":"COMPLETED","sponsor":"Pfizer","isPivotal":false,"enrollment":12,"indication":"Healthy","completionDate":"2010-08"},{"nctId":"NCT07138898","phase":"Phase 2","title":"Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty","status":"NOT_YET_RECRUITING","sponsor":"NYU Langone Health","isPivotal":false,"enrollment":80,"indication":"Rheumatic Disease","completionDate":"2027-09"},{"nctId":"NCT05638932","phase":"N/A","title":"Methodologies for Observational Studies Comparing Inpatient COVID-19 Treatments: IL-6 Receptor Inhibitors and JAK Inhibitors for Hospitalized COVID-19 Patients Receiving Corticosteroid Therapy","status":"COMPLETED","sponsor":"Aetion, Inc.","isPivotal":false,"enrollment":1442,"indication":"COVID-19","completionDate":"2023-09-25"},{"nctId":"NCT00263328","phase":"Phase 2","title":"A Multicenter, Phase 2, Open-label, Controlled, Extension Study For Stage 1 Subjects Of Study A3921009 To Evaluate The Long-term Safety And Efficacy Of Cp-690,550 Versus Tacrolimus, When Co-administer","status":"COMPLETED","sponsor":"Pfizer","isPivotal":false,"enrollment":46,"indication":"Kidney Transplantation","completionDate":"2014-06"},{"nctId":"NCT06172361","phase":"Phase 3","title":"Efficacy and Safety of Induction and Tapering Therapy With Tofacitinib and Glucocorticoid in Patients With Polymyalgia Rheumatica (ITTG PMR): An Open-label 52-week Randomized Controlled Trial","status":"RECRUITING","sponsor":"Zhejiang University","isPivotal":true,"enrollment":98,"indication":"Polymyalgia Rheumatica","completionDate":"2026-01-30"},{"nctId":"NCT06275464","phase":"Phase 1","title":"A Phase 1, 2-Part, Randomized, Double-Blind, Placebo Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BT-600 Single and Multiple Ascending Oral Doses","status":"COMPLETED","sponsor":"Biora Therapeutics, Inc.","isPivotal":false,"enrollment":48,"indication":"Healthy","completionDate":"2024-04-23"},{"nctId":"NCT07406932","phase":"NA","title":"A Study on the Efficacy and Safety of JAK Inhibitors Versus Calcineurin Inhibitors as Initial Therapy for Interstitial Lung Disease Associated With Antisynthetase Syndrome","status":"NOT_YET_RECRUITING","sponsor":"China-Japan Friendship Hospital","isPivotal":false,"enrollment":80,"indication":"Antisynthetase Syndrome, Interstitial Lung Disease (ILD)","completionDate":"2027-07-01"},{"nctId":"NCT01786668","phase":"Phase 2","title":"A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study Of The Efficacy And Safety Of Tofacitinib In Subjects With Active Ankylosing Spondylitis (as)","status":"COMPLETED","sponsor":"Pfizer","isPivotal":false,"enrollment":208,"indication":"Ankylosing Spondylitis","completionDate":"2015-03"},{"nctId":"NCT01184092","phase":"Phase 1","title":"Phase 1, Open-Label, Randomized, Single-Dose, 3-Treatment, 3-Period, Cross-Over, Bioequivalence Study Comparing Phase 2b, Phase 3 And Commercial Image Tablet Formulations Of Tasocitinib (CP-690,550) U","status":"COMPLETED","sponsor":"Pfizer","isPivotal":false,"enrollment":24,"indication":"Rheumatoid Arthritis","completionDate":"2010-09"},{"nctId":"NCT03580343","phase":"Phase 2","title":"Tofacitinib for the Treatment of Inflammatory Eye Disease","status":"UNKNOWN","sponsor":"Washington University School of Medicine","isPivotal":false,"enrollment":5,"indication":"Uveitis, Scleritis","completionDate":"2021-04-04"},{"nctId":"NCT06095128","phase":"Phase 4","title":"An Open-Label, Phase 4, Single-Arm, Multicenter Study to Evaluate the Induction of Response and Remission of Vedolizumab Dual Targeted Therapy With Tofacitinib in Adult Patients With Moderately to Sev","status":"RECRUITING","sponsor":"Takeda","isPivotal":false,"enrollment":65,"indication":"Ulcerative Colitis","completionDate":"2027-07-09"},{"nctId":"NCT01736696","phase":"Phase 1","title":"Phase 1, Investigator-Blind, Subject-Blind, Sponsor-Open, Placebo-Controlled, Two-Week, Multiple Dose Escalation Study In Medically Stable Subjects With Psoriasis To Evaluate The Safety, Tolerability,","status":"COMPLETED","sponsor":"Pfizer","isPivotal":false,"enrollment":59,"indication":"Psoriasis, Immunomodulation","completionDate":"2004-04"},{"nctId":"NCT04799262","phase":"Phase 2","title":"Phase II Study of Efficacy and Safety of Tofacitinib in Patients With Polymyalgia Rheumatica","status":"COMPLETED","sponsor":"RenJi Hospital","isPivotal":false,"enrollment":14,"indication":"Polymyalgia Rheumatica, Effect of Drug","completionDate":"2022-05-01"},{"nctId":"NCT06301373","phase":"NA","title":"Methotrexate Combined With Tofacitinib in the Treatment of Active Rheumatoid Arthritis With a Myeloid-stromal Pathotype: a Randomized, Controlled, Open Label, Multicenter Clinical Study","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","isPivotal":false,"enrollment":130,"indication":"Rheumatoid Arthritis","completionDate":"2030-04-01"},{"nctId":"NCT00414661","phase":"N/A","title":"A Prospective Observational Study To Evaluate Long-Term Safety And Functional Status Of Subjects With Rheumatoid Arthritis Previously Enrolled In Studies Of CP-690,550","status":"COMPLETED","sponsor":"Pfizer","isPivotal":false,"enrollment":162,"indication":"Arthritis, Rheumatoid","completionDate":"2012-02"},{"nctId":"NCT03281304","phase":"Phase 4","title":"A PHASE 3B/4, MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PARALLEL GROUP STUDY OF TOFACITINIB (CP-690,550) IN SUBJECTS WITH ULCERATIVE COLITIS IN STABLE REMISSION","status":"TERMINATED","sponsor":"Pfizer","isPivotal":false,"enrollment":140,"indication":"Ulcerative Colitis","completionDate":"2022-03-18"},{"nctId":"NCT06278402","phase":"Phase 3","title":"Efficacy of Oral Tofacitinib in Moderate to Severe Alopecia Areata, Totalis and Universalis at Tertiary Care Hospital, Karachi.","status":"COMPLETED","sponsor":"Jinnah Hospital","isPivotal":true,"enrollment":30,"indication":"Alopecia Areata, Alopecia Totalis","completionDate":"2024-01-16"},{"nctId":"NCT03736161","phase":"Phase 3","title":"Safety and Efficacy of Tofacitinib vs Methotrexate in the Treatment of Psoriatic Arthritis","status":"COMPLETED","sponsor":"Globe Pharmaceuticals Limited","isPivotal":true,"enrollment":61,"indication":"Psoriatic Arthritis","completionDate":"2019-09-28"},{"nctId":"NCT01932372","phase":"N/A","title":"XELJANZ (REGISTERED) TABLETS 5MG SPECIAL INVESTIGATION (ALL-CASES SURVEILLANCE)","status":"COMPLETED","sponsor":"Pfizer","isPivotal":false,"enrollment":9968,"indication":"Rheumatoid Arthritis","completionDate":"2021-08-24"},{"nctId":"NCT04018001","phase":"N/A","title":"Comparative Analysis of Adherence and Effectiveness Outcomes Between Rheumatoid Arthritis (RA) Patients Treated With Tofacitinib Modified Release (MR) Formulation 11mg Once Daily (QD) and Tofacitinib ","status":"COMPLETED","sponsor":"Pfizer","isPivotal":false,"enrollment":1057,"indication":"Rheumatoid Arthritis","completionDate":"2019-04-25"},{"nctId":"NCT03868072","phase":"Phase 1","title":"An Open-label, Randomized, Fasted, Single Dose, Crossover Study to Evaluate the Bioequivalence of Chong Kun Dang Pharmaceutical \"Chong Kun Dang Tofacitinib Tablet\" and Pfizer Korea Inc. \"XELJANZ 5Mg T","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","isPivotal":false,"enrollment":40,"indication":"Rheumatoid Arthritis","completionDate":"2019-04-20"},{"nctId":"NCT04876781","phase":"N/A","title":"Korean Post-marketing Surveillance for Xeljanz XR (Registered)","status":"RECRUITING","sponsor":"Pfizer","isPivotal":false,"enrollment":200,"indication":"Active Moderate to Severe Rheumatoid Arthritis, Active Ankylosing Spondylitis","completionDate":"2026-06-30"},{"nctId":"NCT01309737","phase":"Phase 3","title":"A Phase 3, Multi-Site, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of The Efficacy And Safety Of 2 Oral Doses Of CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Ps","status":"COMPLETED","sponsor":"Pfizer","isPivotal":true,"enrollment":960,"indication":"Psoriasis","completionDate":"2013-04"},{"nctId":"NCT06438679","phase":"Phase 4","title":"A Single-centric Prospective Single-arm Study of 3T Therapy in the Treatment of MDA5-positive Dermatomyositis","status":"ENROLLING_BY_INVITATION","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","isPivotal":false,"enrollment":133,"indication":"Dermatomyositis","completionDate":"2026-12"},{"nctId":"NCT02812342","phase":"Phase 2","title":"Topical Tofacitinib for the Treatment of Alopecia Areata and Its Variants","status":"COMPLETED","sponsor":"Yale University","isPivotal":false,"enrollment":10,"indication":"Alopecia Areata, Alopecia Totalis","completionDate":"2018-12"},{"nctId":"NCT03643211","phase":"N/A","title":"XELJANZ(REGISTERED) TABLETS 5 MG SPECIAL INVESTIGATION(INVESTIGATION OF LONG-TERM USE IN PATIENTS WITH ULCERATIVE COLITIS)","status":"COMPLETED","sponsor":"Pfizer","isPivotal":false,"enrollment":2016,"indication":"Ulcerative Colitis","completionDate":"2022-11-10"},{"nctId":"NCT05293119","phase":"EARLY/Phase 1","title":"Efficacy of Tofacitinib in Vitiligo-a Randomized Controlled Trial in a Selected Tertiary Level Hospital in Dhaka","status":"UNKNOWN","sponsor":"Pi Research Consultancy Center, Bangladesh","isPivotal":false,"enrollment":80,"indication":"Vitiligo, Effect of Drug","completionDate":"2023-11-30"},{"nctId":"NCT07406035","phase":"Phase 2","title":"A Randomized, Placebo- and Active Drug-Controlled, Double-Blind, Multicenter, Parallel-Group Phase II Clinical Trial to Evaluate the Efficacy and Safety of TQH3906 Capsules in the Treatment of Active ","status":"NOT_YET_RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","isPivotal":false,"enrollment":156,"indication":"Psoriatic Arthritis","completionDate":"2027-11"},{"nctId":"NCT05048238","phase":"Phase 1","title":"Evaluation of Tofacitinib in Prevention of Photosensitivity in Cutaneous Lupus Erythematosus (ALE11)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","isPivotal":false,"enrollment":7,"indication":"Cutaneous Lupus","completionDate":"2024-02-29"},{"nctId":"NCT03016884","phase":"Phase 4","title":"Safety and Tolerability of Herpes Zoster Vaccine in Patients With Rheumatoid Arthritis Immunized Prior to Biologics and Tofacitinib Therapy Initiation","status":"UNKNOWN","sponsor":"HaEmek Medical Center, Israel","isPivotal":false,"enrollment":87,"indication":"Herpes Zoster","completionDate":"2020-07"},{"nctId":"NCT03011281","phase":"N/A","title":"Effectiveness and Safety of Tofacitinib in Korean Patients With Rheumatoid Arthritis","status":"UNKNOWN","sponsor":"Hanyang University","isPivotal":false,"enrollment":378,"indication":"Rheumatoid Arthritis","completionDate":"2021-12"},{"nctId":"NCT04412252","phase":"Phase 2","title":"A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY ASSESSING THE SAFETY AND EFFICACY OF TOFACITINIB IN HOSPITALIZED PARTICIPANTS WITH COVID-19 PNEUMONIA WHO ARE RECEIVIN","status":"WITHDRAWN","sponsor":"Pfizer","isPivotal":false,"enrollment":0,"indication":"COVID-19","completionDate":"2020-10-18"},{"nctId":"NCT04338204","phase":"N/A","title":"Observational Study of Tofacitinib in Ulcerative Colitis in Sweden (ODEN)","status":"RECRUITING","sponsor":"Pfizer","isPivotal":false,"enrollment":120,"indication":"Ulcerative Colitis","completionDate":"2026-03-30"},{"nctId":"NCT06089590","phase":"N/A","title":"Ibd CAncer and seRious Infections in France (I-CARE 2)","status":"RECRUITING","sponsor":"Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives","isPivotal":false,"enrollment":6000,"indication":"IBD, Ulcerative Colitis","completionDate":"2031-03-01"},{"nctId":"NCT00658359","phase":"Phase 2","title":"A Phase 2, Multicenter, Open-label, Active Comparator-controlled, Extension Trial To Evaluate The Long-term Safety And Efficacy Of Cp-690,550 In Renal Allograft Recipients","status":"COMPLETED","sponsor":"Pfizer","isPivotal":false,"enrollment":178,"indication":"Kidney Transplantation","completionDate":"2015-06"},{"nctId":"NCT01710046","phase":"Phase 2","title":"An Exploratory Phase 2a, Randomized, Double-blind, Placebo-controlled, Multicenter Study To Assess Mechanism Of Action (Moa) Of Cp-690,550 In The Skin When Administered Orally At 10 Mg Twice Daily (Bi","status":"COMPLETED","sponsor":"Pfizer","isPivotal":false,"enrollment":12,"indication":"Plaque Psoriasis","completionDate":"2013-11"},{"nctId":"NCT06469424","phase":"N/A","title":"An Active Surveillance, Post-Authorization Study to Characterize the Safety of Tofacitinib in Patients With Moderately to Severely Active Ulcerative Colitis in the Real-World Setting Using Data From t","status":"RECRUITING","sponsor":"Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa","isPivotal":false,"enrollment":104,"indication":"Ulcerative Colitis","completionDate":"2026-03-31"},{"nctId":"NCT03703817","phase":"N/A","title":"TREATMENT SATISFACTION COMPARISON IN RHEUMATOID ARTHRITIS PATIENTS BETWEEN TOFACITINIB CITRATE AND ADALIMUMAB, EACH USED IN RHEUMATOID ARTHRITIS TREATMENT","status":"COMPLETED","sponsor":"Pfizer","isPivotal":false,"enrollment":421,"indication":"Rheumatoid Arthritis","completionDate":"2020-03-12"},{"nctId":"NCT03858725","phase":"Phase 1","title":"A Randomized, Open-label, Fasted, Single Dose, Crossover Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-374 5 mg in Healthy Volunteer","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","isPivotal":false,"enrollment":36,"indication":"Rheumatoid Arthritis","completionDate":"2019-05-08"},{"nctId":"NCT03159936","phase":"EARLY/Phase 1","title":"Open Label Phase 2 Pilot Trial of Oral Tofacitinib in Adult Subjects With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE)","status":"TERMINATED","sponsor":"Tufts Medical Center","isPivotal":false,"enrollment":5,"indication":"Discoid Lupus Erythematosus, Systemic Lupus Erythematosus","completionDate":"2020-06-10"},{"nctId":"NCT01204112","phase":"Phase 1","title":"A Phase 1, Open Label, Fixed-Sequence Study To Estimate The Effect Of Repeat-Dose Rifampin On The Pharmacokinetics Of CP-690,550 In Healthy Volunteers","status":"COMPLETED","sponsor":"Pfizer","isPivotal":false,"enrollment":12,"indication":"Healthy","completionDate":"2010-10"},{"nctId":"NCT06201715","phase":"NA","title":"Efficacy and Safety of Tofacitinib in Patients With Prurigo Nodularis: a Prospective, Observational Pilot Study","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","isPivotal":false,"enrollment":24,"indication":"Prurigo Nodularis, Itch","completionDate":"2025-12-30"},{"nctId":"NCT01143805","phase":"Phase 1","title":"A Phase 1, Open Label, Single Dose, Randomized, Cross Over Study To Estimate The Absolute Oral Bioavailability Of CP-690,550 In Healthy Subjects","status":"COMPLETED","sponsor":"Pfizer","isPivotal":false,"enrollment":12,"indication":"Healthy","completionDate":"2010-08"},{"nctId":"NCT03793439","phase":"Phase 1","title":"Tofacitinib Hypothesis-generating, Pilot Study for Corticosteroid-Dependent Sarcoidosis","status":"COMPLETED","sponsor":"Oregon Health and Science University","isPivotal":false,"enrollment":5,"indication":"Sarcoidosis, Pulmonary, Sarcoidosis Lung","completionDate":"2021-06-24"},{"nctId":"NCT01710020","phase":"Phase 1","title":"Phase 1, Open-Label Study Of The Pharmacokinetics, Non-Renal Clearance And Dialyzability Of CP-690,550 In Subjects With End-Stage Renal Disease Undergoing Hemodialysis","status":"COMPLETED","sponsor":"Pfizer","isPivotal":false,"enrollment":12,"indication":"End-Stage Renal Disease, Hemodialysis","completionDate":"2003-06"},{"nctId":"NCT05580042","phase":"Phase 1","title":"An Open-Label, Single Arm, Phase I Study to Evaluate the Safety and Tolerability of AC-1101 Topical Gel in Patients with Granuloma Annulare","status":"COMPLETED","sponsor":"TWi Biotechnology, Inc.","isPivotal":false,"enrollment":13,"indication":"Granuloma Annulare","completionDate":"2023-11-15"},{"nctId":"NCT05431283","phase":"N/A","title":"Efficacia Nel Mondo Reale di Tofacitinib Sulla Spondiloartropatia Associata Alla Colite Ulcerosa","status":"UNKNOWN","sponsor":"Italian Group for the study of Inflammatory Bowel Disease (IG-IBD)","isPivotal":false,"enrollment":100,"indication":"Ulcerative Colitis, Spondyloarthropathy","completionDate":"2023-12-31"},{"nctId":"NCT05606107","phase":"Phase 4","title":"To Compare the Efficacy and Safety of Low-dose Glucocorticoids and Tofacitinib in Alleviating Moderate to High Disease Activity Rheumatoid Arthritis for 24 Weeks","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","isPivotal":false,"enrollment":230,"indication":"Rheumatoid Arthritis","completionDate":"2024-12-31"},{"nctId":"NCT03975790","phase":"N/A","title":"Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Using a United States Healthcare Claims Database","status":"COMPLETED","sponsor":"Pfizer","isPivotal":false,"enrollment":479,"indication":"Rheumatoid Arthritis","completionDate":"2018-10-02"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"","frequency":"","formulation":""},"formularyStatus":[],"apiManufacturers":[],"developmentCodes":[],"ownershipHistory":[],"therapeuticAreas":["Immunology"],"biosimilarFilings":[],"firstApprovalDate":"","companionDiagnostics":[],"firstApprovalCountry":null,"genericManufacturerList":[],"modality":"Small molecule","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}